NEPH vs FELE vs GWW vs CNMD vs NVCR

For growth investors, Nephros, Inc.

(NEPH) is the stronger pick with 32. 7% revenue growth year-over-year, versus 4. 5% for W. W. Grainger, Inc. (GWW). CONMED Corporation (CNMD) offers the better valuation at 24. 3x trailing P/E (8. 4x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, CONMED Corporation (CNMD) is the cheapest at 24.

3x versus W. W. Grainger, Inc. at 34. 9x. On forward P/E, CONMED Corporation is actually cheaper at 8. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CONMED Corporation wins at 0. 23x versus Franklin Electric Co. , Inc. 's 2. 48x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, W.

W. Grainger, Inc. (GWW) delivered a total return of +167. 8%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: GWW returned +462. 8% versus CNMD's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nephros, Inc.

(NEPH) is the lower-risk stock at 0. 58β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 272% more volatile than NEPH relative to the S&P 500. On balance sheet safety, Nephros, Inc. (NEPH) carries a lower debt/equity ratio of 10% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nephros, Inc.

(NEPH) is pulling ahead at 32. 7% versus 4. 5% for W. W. Grainger, Inc. (GWW). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -64. 6% for CONMED Corporation. Over a 3-year CAGR, NEPH leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

W.

W. Grainger, Inc. (GWW) is the more profitable company, earning 9. 5% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 9. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GWW leads at 15. 0% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, CONMED Corporation (CNMD) is the more undervalued stock at a PEG of 0. 23x versus Franklin Electric Co. , Inc. 's 2. 48x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CONMED Corporation (CNMD) trades at 8. 4x forward P/E versus 27. 7x for W. W. Grainger, Inc. — 19. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CNMD: 112. 2% to $78. 00.

In this comparison, CNMD (2.

2% yield), FELE (1. 1% yield), GWW (0. 8% yield) pay a dividend. NEPH, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, W.

W. Grainger, Inc. (GWW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 0. 8% yield, +462. 8% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GWW: +462. 8%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEPH (Healthcare) and FELE (Industrials) and GWW (Industrials) and CNMD (Healthcare) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NEPH is a small-cap high-growth stock; FELE is a small-cap quality compounder stock; GWW is a mid-cap quality compounder stock; CNMD is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. FELE, GWW, CNMD pay a dividend while NEPH, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.